BioSpace News Archive

- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 30, 2020 and highlighted recent c

Thirty-five abstracts with clinical trial data to be presented, featuring findings across psoriatic arthritis (PsA), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) Sixteen abstracts focus on TREMFYA® (guselkumab) in adults with active PsA, including 52-week safety and efficacy data, spinal disease-related endpoints, as well as analyses that highlight patient-reported outcome measures including fatigue

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be participating in the Credit Suisse 29 th Annual Virtual Healthcare Conference on Tuesday, November 10, 2020. Mr. O’Connor’s presentation will begin at 3:30 p.m. ET and will be webcast live.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 62 nd Annual American Society of Hematology (ASH) meeting being held virtually December 5-8, 2020. Poster presentation details: Poster Title: The Crimson

Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced financial results for the third quarter and nine months ended September 30, 2020.

Clenova is pleased to introduce the Clenova Premium Hand Sanitizing Station: a touchless entryway hand sanitizer dispenser that lights up on approach.

As a multi-cytokine inhibitor, BNZ-1 is a novel immuno-oncology drug that integrates inhibition of malignant cells, activation of tumor immunity, and suppression of inflammation

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen’s lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials. Preclinical studies a

Assemblywoman Latrice Walker and Councilwoman Alicka Ampry-Samuel work with Medly Pharmacy and EmblemHealth to make sure New Yorkers receive the Flu Vaccine

The new initiative will fuel collaboration and discovery about the biology of Down syndrome and its co-occurring medical conditions